Stahler A, et al. – Researchers conducted this study to investigate the effect of the HER2/neu, HER3 receptor as well as their ligands’ neuregulin (NRG1) expression on the outcome of patients with metastatic colorectal cancer (mCRC). They did not identify a prognostic influence of HER2/neu and HER3 overexpression in mCRC. However, the frequency of overexpression was comparable with other studies.